Quick Facts

Therapeutic Domain
Temporary relief of symptoms associated with seasonal and perennial allergic rhinitis.
Management of common cold symptoms.
Relief of upper respiratory allergies.

---

Stahist is indicated for the temporary relief of symptoms resulting from allergic conditions of the upper respiratory tract and common cold. The primary therapeutic use is the management of discomfort associated with seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis. Stahist provides symptomatic relief for a specific set of manifestations, which may include watery eyes, itching of the nose or throat, and repeated sneezing.

Additional indications include the temporary relief of a runny nose and the management of nasal congestion associated with these conditions. By addressing these symptoms, Stahist helps to enhance comfort for individuals experiencing upper respiratory allergies. The medical uses for the active components in this type of formulation are focused on the management of these symptoms.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Stahist?

This section defines the officially documented population eligibility rules for Stahist (Pseudoephedrine, Chlorpheniramine, Dextromethorphan), strictly based on government regulatory labeling.

Populations for Whom Use is Contraindicated

Stahist must not be used by individuals who are currently taking or have stopped taking a Monoamine Oxidase Inhibitor (MAOI) within the past 14 days. Use is also contraindicated in patients with known hypersensitivity to any component of the formulation, newborns or premature infants, and women who are breastfeeding. Absolute contraindication also applies to patients with severe hypertension or severe coronary artery disease.

Age and Condition Restrictions

• Age Eligibility: Use is permitted for Adults and Adolescents (12 years of age and over) and Children 6 to under 12 years. Use is not recommended for children younger than 6 years of age; consult a health professional for this group.
• Conditional Use: A health professional must be consulted before use if the individual has specific pre-existing conditions, including heart disease, high blood pressure, thyroid disease, diabetes mellitus, glaucoma, or prostate enlargement. Similarly, if pregnant, a health professional must be consulted before use. Use in older adults requires caution.

Interactions with other medicines and products

Stahist, a combination of Pseudoephedrine, Chlorpheniramine, and Dextromethorphan, has formally documented interaction patterns that are classified according to regulatory standards.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal regulatory contraindication due to the risk of severe reactions like Hypertensive Crisis and Serotonin Syndrome. Stahist is prohibited for use within 14 days of stopping MAOI therapy, a mandatory timing rule established in official labeling.

Pharmacodynamic and Exposure Interactions

Combining Stahist with other Central Nervous System (CNS) Depressants, including alcohol, opioids, and sedatives, leads to a pharmacodynamic interaction causing additive CNS depression. The risk of Serotonin Syndrome is increased when Stahist is co-administered with other Serotonergic Drugs, such as certain antidepressants. Co-use with Other Sympathomimetics (decongestants) results in additive adrenergic effects.

Metabolism and Clearance Constraints

CYP2D6 Inhibitors may cause a pharmacokinetic interaction, altering the exposure of the Dextromethorphan component. The active ingredient Chlorpheniramine may inhibit the hepatic metabolism of Phenytoin, leading to increased Phenytoin plasma levels. Additionally, official documents note that Urinary Alkalinizing Agents may increase the concentration of Pseudoephedrine by reducing its renal clearance.

How Stahist Works: Pharmacodynamic Mechanism

The action of Stahist is defined by three distinct pharmacodynamic domains targeting different regulatory pathways. The primary action involves antagonism (blocking) at histamine H1 receptors. This interaction prevents histamine from binding, thereby reducing increased vascular permeability and limiting vasodilation, which contributes to the decrease in tissue edema.

Simultaneously, the drug acts as an agonist (activator) at alpha-adrenergic receptors on blood vessel smooth muscle. This activation triggers localized vasoconstriction by engaging sympathetic signaling pathways, resulting in the physical detumescence (shrinkage) of swollen mucosal tissues and affecting tissue volume regulation.

Finally, Stahist exerts an antagonistic effect on muscarinic cholinergic receptors located on exocrine glands. By interrupting the parasympathetic signal that stimulates glandular output, the drug reduces the activity of these secretory cells. The physiological consequence is a decreased production of watery secretions, which contributes to a modulated fluid state in the targeted tissues. These three mechanisms modulate vascular and glandular activity at the system level.

How to Use Stahist: Official Administration Guidelines

The usage of Stahist, a combination product containing Pseudoephedrine, Chlorpheniramine, and Dextromethorphan, is based on standardized administration and dosing principles. This medicine is intended exclusively for oral administration in its approved forms, which include tablets and liquid/syrup formulations.

Administration follows a periodic, as-needed schedule, typically requiring a dose to be taken every 4 to 6 hours. Standardized instructions indicate that users must not exceed 4 doses within any 24-hour period. Furthermore, Stahist is classified for short-term use; continuous administration is generally limited to a maximum of seven consecutive days for temporary symptom relief.

Procedural and Age-Specific Rules

Administration Aspect	Official Instruction Principle
Measurement (Liquid)	Requires the use of a dedicated measuring device (e.g., dosing cup or syringe) for accurate volume and must not be measured with household utensils.
Adult Dosing	Standard dose unit (e.g., 1 tablet or 10 mL of liquid) is administered per interval.
Pediatric Dosing	Children 12 years and older follow the adult regimen. Children 6 to 11 years receive a reduced dose. Use in children under 6 years is generally cautioned against or discouraged.

The overall use protocol is defined by these parameters, establishing a precise time window between doses and a definite time limit for the overall course of use. This structure ensures that administration remains within standardized parameters.

Research Evidence Overview for Stahist

This overview summarizes the type of scientific research and clinical studies conducted on the components of Stahist, focusing on what was measured, the observed patterns, and what remains uncertain.

---

Evidence for Symptomatic Relief of the Common Cold

Research on cold and cough combination products, including the components found in Stahist, primarily relies on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were designed to monitor the effects of the combination compared to a placebo or single ingredients over a period of four to seven days, which is consistent with the duration of the studies conducted. Researchers explored how symptoms change over time and measured outcomes related to physical discomfort, specifically tracking changes in the Total Symptom Score which includes nasal congestion, runny nose, and cough.

Findings describe patterns observed in the studies related to how patients reported their experience regarding discomfort and daily functioning during the short study interval. However, research highlights changes measured during the study period, and findings were mixed when trying to evaluate the effect on individual symptoms, particularly cough intensity. Overall, research provides insight into short-term changes.

---

Evidence for Temporary Relief of Allergic Rhinitis Symptoms

The components in Stahist targeting allergies and congestion have been extensively evaluated through Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies focused on conditions characterized by fluctuating or episodic manifestations, specifically allergic rhinitis (hay fever). Research explored how symptoms change over time and monitored outcomes linked to inflammatory or irritative states, with studies conducted during periods of increased symptom activity. The studies examined outcomes related to physical discomfort, such as the Nasal Symptom Score and associated Ocular symptoms.

Findings describe patterns observed in the studies related to the measurement of nasal and ocular symptoms across the observed populations compared to controls. This evidence contributes to the broader evidence landscape for the use of antihistamine and decongestant combinations in these conditions. However, the available data is often derived from research on the dual-combination products rather than the specific triple-combination that includes the cough suppressant found in Stahist.

---

Research Gaps and Areas of Uncertainty

Authoritative sources have identified several areas where the research evidence is less conclusive or incomplete. One key limitation is that comparative evidence is lacking for the specific triple-combination formula against the full range of other similar single- or dual-agent products. This limits the ability to draw comprehensive conclusions about its relative place in the broader evidence landscape. Furthermore, long-term outcomes are not well characterized, and subgroup findings are uncertain, as the research provides context but not individual predictions.

Key Studies & References Review of cough and cold medicines in children: Tabulated summaries of clinical trials prepared by the TGA to accompany the Report by the External Reviewers (May 2009)

Common questions about Stahist (FAQ)

Q: Is Stahist safe to take during pregnancy?

Official labeling advises that a healthcare professional must be consulted before using Stahist during pregnancy. This caution is advised because some components of the medication may have limited or incomplete safety information available for use during pregnancy.

Q: Where can I find a good overview of the evidence that supports the use of Stahist?

Studies and official information indicate that the components in Stahist have been evaluated primarily through short-term Randomized Controlled Trials. These studies show evidence for providing symptomatic relief of upper respiratory symptoms, such as cough, runny nose, and nasal congestion, when compared to a placebo, supporting the drug's approved use.

Q: How should I properly dispose of expired Stahist?

Official disposal instructions advise against flushing Stahist down the toilet or pouring it into a drain. To ensure proper disposal, it is recommended to consult a pharmacist or local authorized source for information about medication take-back programs in the area.

Q: What happens if I take Stahist with an MAOI?

Taking Stahist with a Monoamine Oxidase Inhibitor (MAOI) is strictly prohibited and is considered a formal regulatory contraindication. This combination can lead to severe adverse reactions, which may include a dangerously sudden increase in blood pressure (hypertensive crisis) or serotonin syndrome. Official labeling mandates that use is prohibited within 14 days of discontinuing MAOI therapy.

Q: What happens if I accidentally take two doses of Stahist too close together?

The official product information directs patients not to exceed the recommended dosage limits or intervals. Exceeding the recommended dosage can lead to an overdose and cause serious adverse effects, which may include seizures, hallucinations, or dangerously high blood pressure. If there is any suspicion of an overdose, contact professional medical services or a Poison Control Center immediately, as advised by regulatory safety guidelines.

Q: Can I cut the Stahist tablets in half to reduce the dose?

Unless the official prescribing information or package insert explicitly states that the tablet is scored and approved for splitting, the practice is generally not recommended. Splitting an unscored tablet may result in an inaccurate dose, which could compromise the drug's intended effectiveness or safety.

Q: What makes Stahist a controlled substance, and what are the specific rules about buying it?

While the combination product is generally not classified as a Controlled Substance, its decongestant component, Pseudoephedrine, is regulated by federal law. This regulation imposes restrictions, such as daily and 30-day quantity limits, and typically requires a purchaser to present identification that is logged in a national system.

How to Store and Dispose of Stahist?

Stahist (chlorcyclizine hydrochloride and pseudoephedrine hydrochloride) must be stored and discarded according to official regulatory requirements to maintain product integrity and ensure safety.

Official Storage Requirements

Stahist must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat and moisture; therefore, it should not be stored in a bathroom. The container must be kept tightly closed in a safe place, always out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Stahist must be properly discarded. Official instructions advise not to flush the medication down the toilet or pour it into a drain unless explicitly directed by an authorized source. Consult a pharmacist for the proper disposal method in your area.